Rejected Device Applicants Conserve R&D Resources, Sidestep Confrontation
This article was originally published in The Gray Sheet
Executive Summary
Implantable device manufacturers who encountered FDA resistance in 2004 after favorable panel reviews are applying novel premarket data collection techniques to avoid conducting further clinical trials
You may also be interested in...
Cyberonics Treatment IDE To Allow For Limited Use Of VNS For Depression
Cyberonics' strategy of obtaining a treatment IDE for its vagus nerve stimulation VNS Therapy for depression will place the device in the hands of more physicians, but will not necessarily help reverse FDA's non-approvable decision
Mentor Files Silicone Implant PMA Amendment, Catches Up To Inamed
Mentor's submission of a silicone gel-filled breast implant PMA amendment, announced Aug. 31, places the aesthetic firm nearly on par with sole U.S. competitor Inamed
Cyberonics’ VNS Therapy Approvable As Last-Resort Depression Fix – Panel
FDA's Neurological Devices Panel set aside its desire for an additional, randomized trial of Cyberonics' VNS Therapy depression indication at a June 15 meeting to review the device in Gaithersburg, Md